Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 8/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.49 |
| ▸ | PLK1 | P53350 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26384521 | 0.85 | PLK1 (0.68) | HDAC6HDAC1HDAC3KMT2ALMNA | |
| SCHEMBL12373076 | 0.85 | HDAC6 (0.54) | HDAC6HDAC1HDAC3MEN1MAPT | |
| SCHEMBL5909057 | 0.84 | CA12 (0.58) | HDAC6HDAC1HDAC3MEN1MAPT | |
| SCHEMBL9072937 | 0.84 | CA1 (0.52) | HDAC6HDAC1HDAC3LMNAHDAC8 | |
| SCHEMBL12368427 | 0.84 | HDAC1 (0.72) | HDAC6HDAC1HDAC3MAPTKMT2A | |
| SCHEMBL826023 | 0.82 | PLK1 (0.68) | HDAC6HDAC1HDAC3MEN1MAPT | |
| SCHEMBL2663047 | 0.81 | PRSS1 (0.48) | HDAC6HDAC1HDAC3MEN1MAPT | |
| SCHEMBL28266759 | 0.81 | RORC (0.61) | EPHX2NR1H4 | |
| SCHEMBL18602133 | 0.81 | KMT2A (0.57) | HDAC6HDAC1HDAC3MAPTKMT2A | |
| SCHEMBL2663103 | 0.81 | ALDH1A1 (0.65) | HDAC6KMT2AHPGDHDAC8EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270877-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270877-A1 | IRE-1alpha INHIBITORS | XBP1, ERN1, ATF4 | HDAC6 1000/4885HDAC1 859/4885HDAC3 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.